Enlivex Ltd. Annual Report - How They Did This Year

I’ve put together this guide to help you understand Enlivex Ltd.’s performance. My goal is to explain their complex filings in plain English so you can decide if this company fits your investment goals.

1. What does this company do?

Enlivex is a unique hybrid. They are a biotech company developing Allocetra™, a cell therapy designed to "reprogram" immune cells to treat life-threatening inflammation, such as sepsis and osteoarthritis.

They have also adopted a "digital treasury" strategy. Instead of holding traditional cash, they keep their reserves in the RAIN cryptocurrency. This marks a major shift from a standard business model to a crypto-backed one.

2. Financial performance: A tale of two worlds

This year’s results are unusual because the company’s "profit" is tied to the price of their digital assets.

• The "Paper" Profit: In 2025, the company reported a $12.4 million profit. However, this was mostly a "paper gain" from the rising value of their RAIN tokens, not from selling medicine.
• The Reality of Operations: The company earned $0 in revenue from its medical products. They lost $18.6 million on operations, mostly due to $14.2 million in research costs and $4.4 million in administrative expenses. They have never made a profit from their medical business.

3. Financial health: The "Going Concern" warning

The company relies on cash and selling digital assets to stay open. By the end of 2025, they had about $4.2 million in cash. Because they have no product sales, they warned investors there is "substantial doubt" about their ability to stay in business. Their future depends on raising money by selling more shares or selling their crypto, which carries significant risk.

4. Major risks: Why this is a high-stakes bet

Three major risks could impact your investment:

• The "Crypto-Volatility" Trap: Because they hold RAIN tokens, the company’s financial health swings with the crypto market. If token prices crash, the company may have to issue more shares to fund research. This reduces your ownership percentage.
• Clinical Uncertainty: Allocetra™ is still in development. There is no guarantee it will pass clinical trials or receive government approval. If the medical data fails, the company has no other products to fall back on, which could lead to a total loss of value.
• Regulatory & Geopolitical Risk: They face complex rules in both biotech and crypto. Also, their headquarters in Ness Ziona, Israel, exposes them to regional conflict, which could disrupt their operations or supply chain.

5. Future outlook

The company plans to continue clinical trials for Allocetra™, specifically for osteoarthritis. They also intend to keep their digital assets as their main reserve. They are betting that their crypto holdings will provide enough money to reach a breakthrough in their medical research.

6. The Bottom Line

Enlivex is no longer a standard biotech company. By tying their finances to volatile digital assets, your investment may swing wildly based on crypto trends, regardless of their medical progress. View this as a high-risk gamble where the company’s survival depends on crypto prices rather than selling medicine.

Before you decide: Ask yourself if you are comfortable with a biotech investment that functions more like a crypto-holding company. If you are looking for a traditional pharmaceutical play with steady revenue, this may not be the right fit for your portfolio.